Phenylketonuria Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, Parenteral), By Product (Dietary Supplement, Drugs), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Pediatric Clinics), By Region & Competition, 2020-2030F
Market Overview
The Global Phenylketonuria (PKU) Treatment Market was valued at USD 502.18 million in 2024 and is projected t%li%grow at a CAGR of 8.25% through 2030. PKU is a rare autosomal recessive metabolic disorder caused by mutations in the PAH gene, which impair the body’s ability t%li%break down phenylalanine, an amin%li%acid found in protein-rich foods. This enzymatic deficiency results in elevated phenylalanine levels in the blood, which can be toxic t%li%the central nervous system if left unmanaged—particularly harmful in early development stages. If untreated, PKU can lead t%li%intellectual disability, behavioral challenges, seizures, and other neurological impairments. The therapeutic landscape is evolving with advances such as pegvaliase (Palynziq), approved by the European Medicines Agency (EMA), which offers effective phenylalanine control in adults with poorly managed PKU. As awareness grows and novel therapies emerge, including enzyme-based drugs and gene therapies, the market is expected t%li%experience robust growth, especially as long-term management options improve outcomes and patient quality of life.
Key Market Drivers
Increasing Gene Therapy Research
Gene therapy is emerging as a transformative driver in the PKU treatment market, aiming t%li%correct the underlying genetic defect responsible for the disorder. As PKU stems from mutations in the PAH gene, gene therapy seeks t%li%restore normal enzyme activity and eliminate the lifelong need for restrictive diets and medical foods. In March 2024, Eton Pharmaceuticals strengthened its metabolic product pipeline by acquiring U.S. rights t%li%PKU GOLIKE from Relief Therapeutics—an advanced, taste-masked, extended-release formulation tailored for PKU patients. The acquisition reflects growing commercial interest in expanding therapeutic options. Gene therapies offer a potentially curative approach, improving dietary freedom and quality of life, thereby increasing patient demand and reshaping the future of PKU care. If successful, gene therapy could redefine treatment standards, positioning it as a critical growth driver for the market.
Key Market Challenges
Limited Treatment Options
Despite advances, PKU management remains constrained by limited treatment choices. The standard therapy involves strict adherence t%li%a low-phenylalanine diet, often excluding common protein sources like meat, dairy, and grains. This restrictive approach can impact social experiences and nutritional satisfaction, leading t%li%reduced adherence. Specialized medical foods, though essential, are often unpalatable and limited in variety, presenting additional compliance barriers. Pharmacological treatments like sapropterin (Kuvan) are not effective for all patients, and are typically used in combination with diet. Access t%li%treatment als%li%varies by region, with some patients lacking access t%li%PKU clinics, prescribed formulas, or newer drugs. Furthermore, historically limited investment in PKU research has delayed therapeutic innovation. The heterogeneity of patient responses t%li%treatment further complicates care, reinforcing the need for diverse and individualized treatment approaches.
Key Market Trends
Nutraceuticals and Supplements
The rise of nutraceuticals and supplements tailored for PKU patients marks a significant trend in improving disease management and quality of life. These products serve as essential dietary components, offering amin%li%acid blends, vitamins, and minerals while minimizing phenylalanine intake. Advanced formulations such as low-protein bread, pasta, and functional foods help expand dietary choices for patients. Supplements are often prescribed as medical foods and are developed t%li%fill nutritional gaps caused by dietary restrictions. Personalization is als%li%gaining prominence, with formulations adapted t%li%age, lifestyle, and PKU severity. Enhanced palatability and convenience have made these supplements easier t%li%integrate int%li%daily routines, improving adherence and patient satisfaction. Regulatory frameworks ensure product safety and efficacy, contributing t%li%broader acceptance and sustained market growth for PKU-targeted nutraceuticals.
Key Market Players
In this report, the Global Phenylketonuria Treatment Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Phenylketonuria Treatment Market.
Available Customizations:
Global Phenylketonuria Treatment Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
The Global Phenylketonuria (PKU) Treatment Market was valued at USD 502.18 million in 2024 and is projected t%li%grow at a CAGR of 8.25% through 2030. PKU is a rare autosomal recessive metabolic disorder caused by mutations in the PAH gene, which impair the body’s ability t%li%break down phenylalanine, an amin%li%acid found in protein-rich foods. This enzymatic deficiency results in elevated phenylalanine levels in the blood, which can be toxic t%li%the central nervous system if left unmanaged—particularly harmful in early development stages. If untreated, PKU can lead t%li%intellectual disability, behavioral challenges, seizures, and other neurological impairments. The therapeutic landscape is evolving with advances such as pegvaliase (Palynziq), approved by the European Medicines Agency (EMA), which offers effective phenylalanine control in adults with poorly managed PKU. As awareness grows and novel therapies emerge, including enzyme-based drugs and gene therapies, the market is expected t%li%experience robust growth, especially as long-term management options improve outcomes and patient quality of life.
Key Market Drivers
Increasing Gene Therapy Research
Gene therapy is emerging as a transformative driver in the PKU treatment market, aiming t%li%correct the underlying genetic defect responsible for the disorder. As PKU stems from mutations in the PAH gene, gene therapy seeks t%li%restore normal enzyme activity and eliminate the lifelong need for restrictive diets and medical foods. In March 2024, Eton Pharmaceuticals strengthened its metabolic product pipeline by acquiring U.S. rights t%li%PKU GOLIKE from Relief Therapeutics—an advanced, taste-masked, extended-release formulation tailored for PKU patients. The acquisition reflects growing commercial interest in expanding therapeutic options. Gene therapies offer a potentially curative approach, improving dietary freedom and quality of life, thereby increasing patient demand and reshaping the future of PKU care. If successful, gene therapy could redefine treatment standards, positioning it as a critical growth driver for the market.
Key Market Challenges
Limited Treatment Options
Despite advances, PKU management remains constrained by limited treatment choices. The standard therapy involves strict adherence t%li%a low-phenylalanine diet, often excluding common protein sources like meat, dairy, and grains. This restrictive approach can impact social experiences and nutritional satisfaction, leading t%li%reduced adherence. Specialized medical foods, though essential, are often unpalatable and limited in variety, presenting additional compliance barriers. Pharmacological treatments like sapropterin (Kuvan) are not effective for all patients, and are typically used in combination with diet. Access t%li%treatment als%li%varies by region, with some patients lacking access t%li%PKU clinics, prescribed formulas, or newer drugs. Furthermore, historically limited investment in PKU research has delayed therapeutic innovation. The heterogeneity of patient responses t%li%treatment further complicates care, reinforcing the need for diverse and individualized treatment approaches.
Key Market Trends
Nutraceuticals and Supplements
The rise of nutraceuticals and supplements tailored for PKU patients marks a significant trend in improving disease management and quality of life. These products serve as essential dietary components, offering amin%li%acid blends, vitamins, and minerals while minimizing phenylalanine intake. Advanced formulations such as low-protein bread, pasta, and functional foods help expand dietary choices for patients. Supplements are often prescribed as medical foods and are developed t%li%fill nutritional gaps caused by dietary restrictions. Personalization is als%li%gaining prominence, with formulations adapted t%li%age, lifestyle, and PKU severity. Enhanced palatability and convenience have made these supplements easier t%li%integrate int%li%daily routines, improving adherence and patient satisfaction. Regulatory frameworks ensure product safety and efficacy, contributing t%li%broader acceptance and sustained market growth for PKU-targeted nutraceuticals.
Key Market Players
- BioMarin Pharmaceutical Inc.
- Synlogic, Inc.
- Retrophin, Inc.
- Daiichi Sanky%li%Company, Limited
- Codexis, Inc.
- SOM Innovation Biotech SL
- Homology Medicines, Inc.
In this report, the Global Phenylketonuria Treatment Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- Phenylketonuria Treatment Market, By Route of Administration:
- Oral
- Parenteral
- Phenylketonuria Treatment Market, By Product:
- Dietary Supplement
- Drugs
- Biopten
- Kuvan
- Phenylketonuria Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Pediatric Clinics
- Phenylketonuria Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Phenylketonuria Treatment Market.
Available Customizations:
Global Phenylketonuria Treatment Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PHENYLKETONURIA TREATMENT MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Oral, Parenteral)
5.2.2. By Product (Dietary Supplement, Drugs)
5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Pediatric Clinics)
5.2.4. By Company (2024)
5.3. Market Map
6. ASIA PACIFIC PHENYLKETONURIA TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Product
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Phenylketonuria Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Product
6.3.1.2.3. By Distribution Channel
6.3.2. India Phenylketonuria Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Product
6.3.2.2.3. By Distribution Channel
6.3.3. Australia Phenylketonuria Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Product
6.3.3.2.3. By Distribution Channel
6.3.4. Japan Phenylketonuria Treatment Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Route of Administration
6.3.4.2.2. By Product
6.3.4.2.3. By Distribution Channel
6.3.5. South Korea Phenylketonuria Treatment Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Route of Administration
6.3.5.2.2. By Product
6.3.5.2.3. By Distribution Channel
7. EUROPE PHENYLKETONURIA TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Product
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Phenylketonuria Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Product
7.3.1.2.3. By Distribution Channel
7.3.2. Germany Phenylketonuria Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Product
7.3.2.2.3. By Distribution Channel
7.3.3. Spain Phenylketonuria Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Product
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Phenylketonuria Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Product
7.3.4.2.3. By Distribution Channel
7.3.5. United Kingdom Phenylketonuria Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Product
7.3.5.2.3. By Distribution Channel
8. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Product
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Phenylketonuria Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Product
8.3.1.2.3. By Distribution Channel
8.3.2. Mexico Phenylketonuria Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Product
8.3.2.2.3. By Distribution Channel
8.3.3. Canada Phenylketonuria Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Product
8.3.3.2.3. By Distribution Channel
9. SOUTH AMERICA PHENYLKETONURIA TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Product
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Phenylketonuria Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Product
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Phenylketonuria Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Product
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Phenylketonuria Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Product
9.3.3.2.3. By Distribution Channel
10. MIDDLE EAST AND AFRICA PHENYLKETONURIA TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Product
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Phenylketonuria Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Product
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Phenylketonuria Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Product
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Phenylketonuria Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Product
10.3.3.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL PHENYLKETONURIA TREATMENT MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE ANALYSIS
16. COMPETITIVE LANDSCAPE
16.1. BioMarin Pharmaceutical Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Synlogic, Inc.
16.3. Retrophin, Inc.
16.4. Daiichi Sankyo Company, Limited
16.5. Codexis, Inc.
16.6. SOM Innovation Biotech SL
16.7. Homology Medicines, Inc.
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PHENYLKETONURIA TREATMENT MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Oral, Parenteral)
5.2.2. By Product (Dietary Supplement, Drugs)
5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Pediatric Clinics)
5.2.4. By Company (2024)
5.3. Market Map
6. ASIA PACIFIC PHENYLKETONURIA TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Product
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Phenylketonuria Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Product
6.3.1.2.3. By Distribution Channel
6.3.2. India Phenylketonuria Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Product
6.3.2.2.3. By Distribution Channel
6.3.3. Australia Phenylketonuria Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Product
6.3.3.2.3. By Distribution Channel
6.3.4. Japan Phenylketonuria Treatment Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Route of Administration
6.3.4.2.2. By Product
6.3.4.2.3. By Distribution Channel
6.3.5. South Korea Phenylketonuria Treatment Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Route of Administration
6.3.5.2.2. By Product
6.3.5.2.3. By Distribution Channel
7. EUROPE PHENYLKETONURIA TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Product
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Phenylketonuria Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Product
7.3.1.2.3. By Distribution Channel
7.3.2. Germany Phenylketonuria Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Product
7.3.2.2.3. By Distribution Channel
7.3.3. Spain Phenylketonuria Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Product
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Phenylketonuria Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Product
7.3.4.2.3. By Distribution Channel
7.3.5. United Kingdom Phenylketonuria Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Product
7.3.5.2.3. By Distribution Channel
8. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Product
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Phenylketonuria Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Product
8.3.1.2.3. By Distribution Channel
8.3.2. Mexico Phenylketonuria Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Product
8.3.2.2.3. By Distribution Channel
8.3.3. Canada Phenylketonuria Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Product
8.3.3.2.3. By Distribution Channel
9. SOUTH AMERICA PHENYLKETONURIA TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Product
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Phenylketonuria Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Product
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Phenylketonuria Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Product
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Phenylketonuria Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Product
9.3.3.2.3. By Distribution Channel
10. MIDDLE EAST AND AFRICA PHENYLKETONURIA TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Product
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Phenylketonuria Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Product
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Phenylketonuria Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Product
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Phenylketonuria Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Product
10.3.3.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL PHENYLKETONURIA TREATMENT MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE ANALYSIS
16. COMPETITIVE LANDSCAPE
16.1. BioMarin Pharmaceutical Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Synlogic, Inc.
16.3. Retrophin, Inc.
16.4. Daiichi Sankyo Company, Limited
16.5. Codexis, Inc.
16.6. SOM Innovation Biotech SL
16.7. Homology Medicines, Inc.
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
